[Case report of mucormycosis in a patient with secondary methimazole-induced agranulocytosis].
Agranulocytosis is a rare side effect of antithyroid drugs, it occurs in less than 0.5% of patients, usually during the first few months of treatment. It is considered to be the most serious adverse effect of these medications since it may be complicated by serious, life-threatening infections. Mucormycosis is a severe mycotic infection that usually develops in immunocompromised hosts, such aspatients with diabetes mellitus, hematologic malignancies or immunosuppressive therapy. The association of mucormycosis with methimazole-induced agranulocytosis has not been previously described. The objective of this case presentation is to analyze the case ofa woman with diffuse toxic goiter and methimazole-induced agranulocytosis who developed rhino-palatal mucormycosis.
Ramírez
Claudia
C
Departamentos de Endocrinologla, Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, México D.F., México.
Hernández
Alex Francisco
AF
Méndez
Verna
V
Trejo
Silvia
S
Contreras
Roxana
R
Espinosa de los Monteros
Ana Laura
AL
Gómez
Luz Maria
LM
Mercado
Moisés
M
D000328:Adult; D000380:Agranulocytosis / Q000139:chemically induced*; D013956:Antithyroid Agents / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008713:Methimazole / Q000009:adverse effects*; D009091:Mucormycosis / Q000139:chemically induced*
D013956:Antithyroid Agents; D008713:Methimazole